Finanzen von Actuate Therapeutics Inc (ACTU)ACTUActuate Therapeutics Inc

In the context of the broader market, ACTU competes directly with industry leaders such as BLRX and CPHI. With a market capitalization of $42.75M, it holds a leading position in the sector. When comparing efficiency, ACTU's gross margin of N/A stands against BLRX's 79.38% and CPHI's 8.81%. Such benchmarking helps identify whether Actuate Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Actuate Therapeutics has shown a significant decline in net income, with losses ranging from -4,553,953 USD to -6,597,961 USD over the last few quarters. The current ratio is 1.25, indicating some liquidity, but the company is still facing financial instability.